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Summary
Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the
surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical
studies with lumiliximab alone and in combination with fludarabine, cyclo-
phosphamide and rituximab (FCR) established its potential efficacy and
tolerability. The 152CL201 trial [Lumiliximab with fludarabine, cyclophos-
phamide and rituximab (FCR) versus FCR alone in subjects with relapsed
CLL; LUCID] was a phase 2/3, randomized (1:1), open-label, multicentre
study of lumiliximab in combination with FCR versus FCR alone in
patients with relapsed CLL. Six hundred and twenty-seven patients were
randomized to either arm. Overall the combination of lumiliximab with
FCR was not significantly better than FCR alone (overall response rate 71%
vs. 72%, complete response rate 16% vs. 15%, median progression-free sur-
vival 24.6 vs. 23.9 months respectively, for FCR with and without lumilix-
imab). There was a slightly increased incidence of adverse events with
lumiliximab but these increases did not appear to lead to differences in
eventual outcomes. An interim analysis failed to show sufficient efficacy of
the combination of lumiliximab with FCR. The study was therefore
stopped early for lack of efficacy. Despite the eventual outcome, the LUCID
trial is one of the largest studies that provides valuable insight into the effi-
cacy and tolerability of FCR as a therapeutic option for patients with
relapsed CLL.
Keywords: CD23, chronic lymphocytic leukaemia, small lymphocytic
lymphoma, lumiliximab.
Chronic lymphocytic leukaemia (CLL) is the most common
adult leukaemia and is defined by the expression of CD5 and
CD23 on the surface of leukaemic B-cells. Lumiliximab is a
chimeric CD23 targeting monoclonal antibody containing
cynomolgus macaque variable regions and human constant
regions (Reichert, 2004; Christian & Lin, 2008). The CD23
antigen (FceRII, FCER2), is a 45-kDa, type II transmembrane
glycoprotein of the C-type lectin family that functions as a
low-affinity receptor for IgE (Kijimoto-Ochiai, 2002;
Kijimoto-Ochiai et al, 2004), and has been postulated to play
a role in modulating the production of IgE by B cells. More-
over, it has also been shown to be involved in promoting the
survival of germinal centre B cells (Gordon et al, 1991; Liu
et al, 1991) and its expression is highly up-regulated in nor-
mal activated follicular B cells and in CLL B cells (Caligaris-
Cappio & Hamblin, 1999; Lopez-Matas et al, 2000). This
selective increase in membrane CD23 (mCD23) density on a
subset of normal B cells has been shown to result in B-cell
proliferation and is also associated with the proliferation cen-
tres of lymph nodes in CLL patients (Fournier et al, 1992;
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Lampert et al, 1999). Importantly, crosslinking of mCD23 on
leukaemic cells results in a negative growth signal, suggesting
that CD23 may be involved in B-cell CLL proliferation
(Fournier et al, 1992; Lampert et al, 1999; Reichert, 2004).
Serum CD23 (sCD23) has also been shown to correlate with
advanced disease status and may be of prognostic importance
(Sarfati et al, 1996; Robak, 2008).
Preclinical studies with lumiliximab showed that it medi-
ates apoptosis of CLL and other CD23-positive transformed
lymphoma cells. This activity was dose-dependent and pri-
marily through direct cytotoxicity and caspase-9 and three
activation, as it was found not to mediate significant anti-
body-dependent cell-mediated cytotoxicity or complement
activation against CLL cells in vitro (Pathan et al, 2008).
These studies also revealed in vitro synergistic activity of the
combination of lumiliximab with rituximab and fludarabine.
In vivo studies utilizing a disseminated lymphoma mouse
model also established the activity of lumiliximab and its
synergistic activity with rituximab and fludarabine. A subse-
quent phase one study in 46 heavily pretreated CLL patients
established its safety and efficacy. The maximal tolerated dose
was not achieved, however, no significant responses were
observed with lumiliximab monotherapy (Byrd et al, 2007).
Given its in-vivo synergistic activity with rituximab or flu-
darabine and early phase clinical trials showing lack of signif-
icant myelosuppression, immunosuppression or drug-related
toxicity, lumiliximab was felt to be an attractive agent for
use in combination with existing chemoimmunotherapeutic
regimens. Lumiliximab was subsequently studied in combina-
tion with fludarabine, cyclophosphamide and rituximab
(FCR) in a phase 1/2 study in 31 patients with previously
treated CLL and resulted in an overall response rate (ORR)
of 71% with a complete response of 52% (Byrd et al, 2010).
This compared favourably to existing activity reported with
the use of FCR alone in patients with previously treated CLL
(Keating et al, 2005; Wierda et al, 2005). The 152CL201
(Lumiliximab with fludarabine, cyclophosphamide and ritux-
imab (FCR) versus FCR alone in subjects with relapsed CLL;
LUCID) trial was therefore designed as an open label, multi-
centre, phase 2/3 randomized comparative study to deter-
mine the efficacy of the combination of lumiliximab (L) with
or without FCR in patients with relapsed chronic lympho-
cytic leukaemia.
Methods
Study design and patients
A Phase 2/3, randomized (1:1), open-label, multicentre, study
of lumiliximab in combination with fludarabine, cyclophos-
phamide and rituximab (FCR+L) versus FCR alone was con-
ducted at 150 sites in 22 countries. Patients with previously
treated CD23+ and CD20+ relapsed CLL, as defined by the
National Cancer Institute (NCI) 1996 working group criteria
(Cheson et al, 1996), were enrolled in the trial. Additional
inclusion criteria included patients who had received at least
1, but no more than 2, prior single-agent or combination
treatments for CLL, Rai Stage III or IV (Binet Stage C), or
Rai Stage I or II (Binet Stage A or B) if determined to have
disease progression as evidenced by rapid doubling of
peripheral lymphocyte count, progressive lymphadenopathy,
progressive splenomegaly, or B symptoms. Patients had an
Eastern Cooperative Oncology Group performance status of
≤2 (Oken et al, 1982) with acceptable hepatic and renal func-
tion. The study protocol was reviewed and approved by the
institutional review board or ethics committee of each insti-
tution and each patient provided written informed consent
before enrolment. Patients were stratified by Rai Stage (I/II
versus III/IV) and number of prior CLL treatment regimens
(1 versus 2).
The primary objective of the study was to determine the
efficacy of FCR+L compared with FCR alone for the treat-
ment of subjects with relapsed CLL. The secondary objective
of this study was to evaluate and compare the safety profile
of subjects treated with FCR+L versus FCR alone.
Study procedures
Study treatments were given over six 28-d treatment cycles.
Treatment consisted of fludarabine 25 mg/m2 IV infusion
over at least 10–30 min on days 1–3 of cycles 2–6 and cyclo-
phosphamide 250 mg/m2 IV infusion over at least 10–
30 min on days 1–3 of cycles 2–6. Both fludarabine and
cyclophosphamide were administered on days 2–4 of cycle 1.
Rituximab was administered at 50 mg/m2 IV over 4 h with-
out dose-rate escalation on day 1 of cycle 1, and 450 mg/m2
(50 mg/h during the first hour, increased by 50-mg/h incre-
ments every 30 min to a maximum of 400 mg/h) on day 3
of cycle 1. Subsequent doses of rituximab were administered
on day 1 of cycles 2–6 at 500 mg/m2 IV (100 mg/h, increase
in 100-mg/h increments no less than every 30 min to a
maximum of 400 mg/h). Patients randomized to the lumilix-
imab arm received 50 mg/m2 IV over 4 h without dose-rate
escalation on day 2 of cycle 1, and 450 mg/m2 (50 mg/h dur-
ing the first hour, increased by 50-mg/h increments every
30 min to a maximum of 400 mg/h) on day 4 of cycle 1.
Subsequent doses of lumiliximab were administered on day 1
of cycles 2–6 at 500 mg/m2 IV (over a minimum period of
2 h without dose-rate escalation). On Day 2 of Cycle 1,
lumiliximab (if applicable) was given first, followed by flu-
darabine and cyclophosphamide. On days 3 and 4 of Cycle 1,
the antibody infusion (rituximab and lumiliximab, if applica-
ble) preceded the fludarabine and cyclophosphamide injec-
tions. All patients received antimicrobial prophylaxis for
Pneumocystis jirovecii with cotrimoxazole or an equivalent,
and antiviral prophylaxis against herpes simplex and varicella
zoster reactivation with acyclovir at 400 mg twice a day or
equivalent throughout the treatment period and as clinically
indicated. Growth factors were used at the discretion of the
investigators.
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Response was assessed according to the NCI revised guide-
lines (Cheson et al, 1996) during the treatment period and at
weeks 13, 25, 29 and 33, then every 3 months up to month
48, or until disease progression, subsequent CLL therapy,
death, or when all subjects had passed at least the Week 33
visit or had withdrawn from the study, whichever came first.
Complete and partial responses (CRs and PRs) were con-
firmed at least 8 weeks (≥56 d) after the response criteria
were first met.
Interim analyses
The primary endpoint was CR rate and up to three analyses
were to be performed during the study (two interims and a
final). The interim analyses were to compare efficacy with
respect to CR rate. The first interim analysis was based on
CR rates confirmed by computerized tomography (CT) scan
as assessed by an Independent Review Committee; the second
interim analysis and the final analysis were to be based on
Investigator-assessed CR rates without the use of CT scans.
At the first interim analysis of 195 subjects up to at least
Week 33 or withdrawn from the study, whichever came first,
an Independent Data Monitoring Committee determined
that there was a risk of the study being underpowered for
the planned progression-free survival (PFS) endpoint analy-
sis; recruitment into the study was stopped; and the protocol
was amended to update the primary analysis to CR rate only
(n = 627).
The second interim analysis was utilized to determine if
the study should proceed to the final analysis based on
whether the pre-specified stopping boundary demonstrated
sufficient efficacy. This interim analysis showed that there
was no benefit of adding lumiliximab to FCR; therefore, the
decision was made not to proceed to the final analysis and
the study was terminated early.
Statistical analysis
Two populations were used to analyse the efficacy data: The
Intent-to-Treat (ITT) Population was defined as all subjects
randomized into the study (N = 627). This sample size was
expected to provide approximately 98% power to detect a
difference between Investigator-assessed complete response
(CR) rates without the use of CT scans of 28.1% (FCR+L)
and 14.5% (FCR) with an alpha of 0.05 (2-sided) using an
unpooled estimate of the variance. The study was initially
designed as a randomized phase II trial under these assump-
tions but, because of the early accrual rates, was changed to
a phase III design with planned accrual of 900 patients.
However, given the results of the first interim analysis, the
study design was reverted to the original phase II design.
Subjects were analysed by the treatment group to which they
were randomized. The second interim analysis examined the
second efficacy population (Interim Analysis of Efficacy Pop-
ulation 2), which was defined as the first 390 ITT subjects
who had passed the Week 33 visit or had withdrawn from
the study, whichever came first. The secondary endpoints of
PFS and OS were evaluated for the ITT Population only. The
primary endpoint of CR rate and the secondary endpoints of
best response, ORR and duration of response (DR) was eval-
uated for the Interim Analysis 2 Efficacy Population 2.
CR rate was summarized by treatment group and the 95%
confidence intervals (95% CIs) were calculated using the nor-
mal approximation to the binomial method. A difference in
CR rates between treatment groups was tested using a Coch-
ran-Mantel-Haenszel statistic with covariates to control for
Rai Stage at study entry (I/II versus III/IV) and the number
of prior CLL treatment regimens (1 versus 2).
For the time-to-event endpoints, DR, PFS and OS, median
time-to-event measures were calculated using the Kaplan–
Meier method and the associated 2-sided 95% CIs were cal-
culated based on the sign test. Formal hypothesis tests were
not performed and P-values were not calculated due to the
limited amount of information expected for these endpoints.
DR, PFS and OS were summarized graphically by treatment
group using Kaplan–Meier estimated survival curves.
Subjects who received subsequent CLL therapy prior to
progression or death were discontinued from the study and
entered into long-term follow-up. Subjects were censored at
the date of their last response assessment in follow-up or last
assessment in long-term follow up, whichever was later, if an
event did not occur. Data collected through the long-term
follow-up portion of the study were used to determine DR,
PFS and OS. The Medical Dictionary for Regulatory Activi-
ties (MedDRA) coding system, Version 12.0, was used to
classify AEs (International Conference on Harmonization,
2009). AEs were defined as all reported events with a start
date on or after Study Day 1 or an increase in severity on or
after Study Day 1 and graded on a scale of 1–5 according
to the adult NCI Common Terminology Criteria for AEs
(Version 3.0) (Accessible at http://ctep.cancer.gov/protocol
Development/electronic_applications/docs/ctcaev3.pdf).
Results
Six hundred and twenty-seven subjects were randomized and
615 subjects were dosed in this study. The subject profile is
detailed in Fig 1. Demographics were similar for both treat-
ment groups. Most subjects were white (94%) and male
(70%), and ranged in age from 34 to 82 years old. Baseline
disease characteristics were similar for both treatment groups,
including subject distribution of the two stratification factors,
Rai stage at study entry and number of prior CLL treatments
(Table I).
The CR rate showed no significant difference between the
treatment groups: 33 (16%) subjects in the FCR+L treatment
group and 28 (15%) subjects in the FCR treatment group
(P-value = 0.782). The secondary efficacy endpoints analysed
were best response (CR), nodular partial response (nPR),
partial response (PR), stable disease, progressive disease,
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unevaluable or not evaluated) and ORR without CT scans;
DR, PFS and OS. ORR was defined as any best response of
CR, nPR or PR. As with the primary efficacy endpoint, the
best response did not show a difference between the treat-
ment groups (Table II). Of note, most of the CRs were
observed in patients with early stage disease and with one
prior line of therapy.
The median DR (for subjects with a best response of CR/
nPR/PR) was 27 months for subjects in the FCR+L treatment
group and 24.5 months for subjects in the FCR treatment
group (Fig 2). The median PFS was 24.6 months for subjects
in the FCR+L treatment group and 23.9 months for subjects
in the FCR treatment group (Fig 3). The median OS was not
reached for either treatment group due to the lack of suffi-
cient follow-up after the early termination of the study
(Table II and Fig 4).
Data on treatment tolerability were available for the first
390 subjects randomized to the study. Of these subjects, nine
subjects did not receive study treatment and were not
included in the treatment tolerability analysis. Sixty percent
of subjects in both treatment groups completed Cycle 6 and
119 (59%) of the 202 subjects in the FCR+L treatment group
and 105 (59%) of the 179 subjects in the FCR treatment
group completed all six cycles of study treatment. Infusion-
related reactions occurred in 37 (12%) patients in both treat-
ment groups.
Six hundred and three (98%) subjects experienced an AE:
307 (99%) subjects in the FCR+L treatment group and 296
(97%) subjects in the FCR treatment group. There was a
slight increase in the incidence of prolonged cytopenias
(defined as duration >28 d) in the FCR+L versus FCR treat-
ment groups (Table III). There was also a slight increase in
the incidence of tumour lysis syndrome, occurring in 6 (2%)
subjects in the FCR+L treatment group compared to 2
(<1%) subjects in the FCR treatment group. None of the
tumour lysis syndrome events led to discontinuation of study
treatment. There were no apparent differences in infections
or infusion reactions in the FCR+L and FCR treatment
groups. Overall, the severity of AEs was similar between the
treatment groups (Table III).
Two hundred and forty-four (40%) subjects experienced
a treatment-emergent serious AE (SAE): 125 (40%) subjects
in the FCR+L treatment group and 119 (39%) subjects in
the FCR treatment group. The most common events were
febrile neutropenia [33 (11%) subjects in the FCR+L treat-
ment group and 29 [10%] subjects in the FCR treatment
group], pneumonia [12 (4%) subjects in the FCR+L treat-
ment group and 13 (4%) subjects in the FCR treatment
group] and neutropenia [12 (4%) subjects in the FCR+L
treatment group and 8 (3%) subjects in the FCR treatment
group].
Two hundred and thirty-five (76%) of the 310 subjects
who received lumiliximab experienced a lumiliximab-related
AE. The most common events were: neutropenia (150 [48%]
subjects), nausea [75 (24%) subjects], thrombocytopenia [66
(21%) subjects] and anaemia [56 (18%) subjects].
One hundred and eighty-three (30%) of the treated sub-
jects experienced an AE that led to discontinuation of treat-
ment: 95 (31%) subjects in the FCR+L treatment group and
88 (29%) subjects in the FCR treatment group. The majority
of subjects who experienced an AE leading to discontinua-
tion of treatment reported neutropenia or thrombocytopenia
as the specific AE.
There were slight trends of increased prolonged leuco-
penia, neutropenia, thrombocytopenia and pancytopenia
reported as SAEs in the FCR+L compared to FCR treatment
groups. Importantly, there was no imbalance in the incidence
of infections or fatal outcomes of cytopenia SAEs.
Fig 1. Subject Profile. CLL, chronic lympho-
cytic leukaemia; FCR, fludarabine, cyclophos-
phamide and rituximab: FCR+L, FCR and
lumiliximab.
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The top five infectious events for the FCR+L treatment
group were upper respiratory tract infection in 30 (10%)
subjects, bronchitis in 21 (7%) subjects, nasopharyngitis in
18 (6%) subjects, pneumonia in 17 (5%) subjects and respi-
ratory tract infection in 15 (5%) subjects. Comparable inci-
dences were observed in the FCR treatment group, where the
top five events included upper respiratory tract infection in
35 (11%) subjects, bronchitis in 25 (8%) subjects, pneumo-
nia in 23 (8%) subjects, sinusitis in 16 (5%) subjects, and
urinary tract infection in 14 (5%) subjects. Fatal infection
incidences were similar between the two treatment groups.
Sixty-seven subjects died. Of those, one subject did not
receive study treatment. Thirty-seven subjects had deaths
related to an AE. Lumiliximab-related AEs leading to death
were reported for six subjects and were primarily related to
infectious complication and pancytopenia.
Discussion
Herein we describe study 152CL201 (LUCID) that was origi-
nally designed as a pivotal study to support the registration
of lumiliximab in the treatment of patients with relapsed
CLL. This multicentre randomized trial compared the effi-
cacy of FCR with lumiliximab to FCR alone, as measured by
response rate and PFS. Based on a lack of sufficient efficacy
shown in the second interim analysis for LUCID, a decision
was made not to proceed to the final analysis and the study
was terminated early due to lack of efficacy.
Table I. Demographics (Intent to Treat Population).
FCR+L
(n = 316)
FCR
(n = 311)
Age, years; mean/median
(range)
61.20/61.00
(34.0, 82.0)
61.11/61.00
(34.0, 82.0)
Age groups, n (%)
<65 years 192 (61) 200 (64)
65–74 years 108 (34) 94 (30)
≥75 years 16 (5) 17 (5)
Male Gender, n (%) 218 (69) 218 (70)
Race, n (%)
Asian 8 (3) 19 (6)
Black or African
American
4 (1) 3 (<1)
White 301 (95) 286 (92)
Other 3 (<1) 3 (<1)
BMI, kg/m2; mean/median
(range)
27.14/26.75
(17.9, 49.3)
26.95/25.96
(16.7, 54.9)
BSA; mean/median (range) 1.911/1.930
(1.40, 2.53)
1.907/1.900
(1.36, 2.66)
Rai stage at diagnosis, n (%)
0 67 (21) 64 (21)
I 121 (38) 109 (35)
II 79 (25) 79 (25)
III 17 (5) 16 (5)
IV 15 (5) 27 (9)
NK 15 (5) 14 (5)
ND 2 (<1) 2 (<1)
Rai stage at study entry, n (%)
I 79 (25) 74 (24)
II 120 (38) 129 (41)
III 42 (13) 38 (12)
IV 75 (24) 70 (23)
Years since diagnosis;
mean/median (range)
5.68/5.08
(0.2, 21.1)
5.63/4.81
(0.1, 36.2)
Months since most recent
relapse; mean/median (range)
5.27/2.56
(0.3, 91.0)
5.34/2.60
(0.2, 76.0)
Prior CLL treatments, n;
median (range)
1 (1–6) 1 (1–6)
Prior CLL treatments, n (%)
1 191 (60) 194 (62)
2 115 (36) 106 (34)
3 7 (2) 6 (2)
4 1 (<1) 2 (<1)
5 1 (<1) 1 (<1)
6 1 (<1) 2 (<1)
Prior fludarabine-containing treatments, n (%)
0 163 (52) 179 (58)
1 138 (44) 120 (39)
2 12 (4) 10 (3)
3 0 1 (<1)
5 1 (<1) 1 (<1)
6 2 (<1) 0
Prior rituximab-containing treatments, n (%)
0 248 (78) 256 (82)
1 52 (16) 49 (16)
2 15 (5) 5 (2)
Table I. (Continued)
FCR+L
(n = 316)
FCR
(n = 311)
4 0 1 (<1)
5 1 (<1) 0
ECOG performance status, n (%)
0 200 (63) 196 (63)
1 103 (33) 102 (33)
2 13 (4) 13 (4)
Presence of B-symptoms, n (%)
Weight loss > 10% 13 (4) 9 (3)
Grade 2 or 3 fatigue 28 (9) 22 (7)
Fever/night sweats >2 weeks 60 (19) 48 (15)
Presence of splenomegaly, n (%) 236 (75) 222 (71)
Presence of lymphadenopathy, n (%) 316 (100) 309 (99)
Interphase FISH status, n (%)
11q- 44 (21) 49 (27)
13q- 114 (55) 104 (57)
17p- 19 (9) 15 (8)
IGHV Mutational Status
Unmutated 107 (52) 92 (50)
CLL, chronic lymphocytic leukaemia; FCR, fludarabine, cyclophos-
phamide and rituximab: FCR+L, FCR and lumiliximab; BMI, body
mass index; BSA, body surface area; ECOG, Eastern Cooperative
Oncology Group; FISH, fluorescence in situ hybridization; NK, not
known; ND, not done.
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Table II. Trial Outcomes (N = 390).
FCR+L
(n = 207)
FCR
(n = 183) P-value
Patients completing Cycle 3, n (%) 182 (90) 157 (88)
Patients completing Cycle 6, n (%) 121 (60) 107 (60)
Investigator assessed CR/PR/nPR rate for efficacy population (NCI criteria), n (%)
ORR 148 (71)
(95% CI, 65–78)
131 (72)
(95% CI, 65–78)
0.92
CR 33 (16)
(95% CI, 11–21)
28 (15)
(95% CI, 10–21)
0.782
nPR/PR 115 (56)
(95% CI, 49–62)
103 (56)
(95% CI, 49–63)
0.91
SD 40 (19) 32 (17)
PD 3 (1) 3 (2)
Unevaluable 1 1
Not evaluated 15 (7) 16 (9)
Median Duration of response (in months)
CR/nPR/PR 27
(95% CI, 21.6–27.8)
24.5
(95% CI, 20.4-NR)
NS
CR NR
(95% CI, NR-NR)
NR
(95% CI, 20.4-NR)
nPR/PR 21.7
(95% CI, 20.4–27.5)
22.8
(95% CI, 15.7–NR)
Median PFS (months) 24.6
(95% CI, 23.6–30.8)
Censored n (%) = 227 (73)
23.9
(95% CI, 18.6–27.3)
Censored n (%) = 227 (73)
NS
Median OS (months) NR
Censored n (%) = 288 (91)
NR
Censored n (%) = 272 (87)
NS
CR rate, n (%)
Rai Stage I/II and 1 Prior CLL treatment 16 (8) 19 (10) 0.782
Rai Stage III/IV and 1 Prior CLL treatment 9 (4) 4 (2)
Rai Stage I/II and 2 Prior CLL treatments 4 (2) 4 (2)
Rai Stage III/IV and 2 Prior CLL treatments 4 (2) 1 (<1)
CLL, chronic lymphocytic leukaemia; FCR, fludarabine, cyclophosphamide and rituximab: FCR+L, FCR and lumiliximab; ORR, overall response
rate; CR, complete response; PR, partial response; nPR, nodular partial response; SD, stable disease; PD, progressive disease; PFS, progression-free
survival; OS, overall survival; NR, not reached; NS, not significant; 95% CI, 95% confidence interval.
Fig 2. Kaplan–Meier curve of Duration of
Response. FCR, fludarabine, cyclophosphamide
and rituximab: FCR+L, FCR and lumiliximab.
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Lumiliximab, administered as a single agent, weekly for
4 weeks, in a Phase 1 study in subjects with relapsed or refrac-
tory CLL, was well tolerated and had modest evidence of clini-
cal activity (e.g., transient decreases in absolute lymphocyte
counts [ALCs] and lymph node bulk) (Byrd et al, 2007). Pre-
clinical efficacy of combination treatment justified exploration
with other therapies used in CLL, such as FCR (Keating et al,
2005; Wierda et al, 2005). Lumiliximab administered in com-
bination with FCR, monthly for six cycles, in subjects with
relapsed CLL in a Phase 1/2 study demonstrated an acceptable
safety profile and suggestion of higher complete response as
compared to what was historically expected with FCR alone
(Keating et al, 2005; Wierda et al, 2005, 2006; Byrd et al,
2010). A comparison of these safety results with published
results from the REACH (Rituximab in the Study of Relapsed
Chronic Lymphocytic Leukemia) trial, of FCR compared to FC
in patients with relapsed CLL (Robak et al, 2010), indicated
that the administration of lumiliximab in combination with
the FCR regimen did not appear to increase the toxicity of the
FCR regimen (Byrd et al, 2010). However in this large ran-
domized phase 2/3 study there was a slightly increased inci-
dence of AEs of prolonged cytopenias and tumour lysis
syndrome but these increases did not appear to lead to differ-
ences in the eventual outcome, such as infections or fatalities.
In the present study, the incidence of adverse events resulting
in discontinuation of treatment was also fairly similar to the
FCR arm of the REACH trial (Robak et al, 2010). Also, we
observed a similar ORR, but lower CR rate and median PFS,
despite a fairly similar previously treated population with
high-risk disease. Moreover, the second interim analysis failed
to show sufficient efficacy of the combination of FCR+L com-
pared to FCR alone based on the primary endpoint of CR. The
sponsor therefore decided not to pursue further development
of lumiliximab in CLL. As a result, the study did have not suf-
ficient long-term follow-up to determine the true difference in
PFS and OS.
Fig 3. Kaplan–Meier curve of Progression-Free
Survival. FCR, fludarabine, cyclophosphamide
and rituximab: FCR+L, FCR and lumiliximab.
Fig 4. Kaplan–Meier curve of Overall Survival.
FCR, fludarabine, cyclophosphamide and ritux-
imab: FCR+L, FCR and lumiliximab.
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Preclinical studies with lumiliximab established its activity
in mediating caspase-dependent apoptosis but not comple-
ment- and antibody-dependent cellular cytotoxicity against
primary CLL B-cells (Pathan et al, 2008). Moreover, it was
also shown that lumiliximab synergistically enhanced the effi-
cacy of rituximab and fludarabine in in vitro assays (Pathan
et al, 2008). Despite these promising preclinical results, lumi-
liximab failed to demonstrate meaningful clinical benefit in
subsequent trials. These results highlight the limitation of in
vitro assays in predicting the true clinical benefit of novel
agents. This is especially true for immune-modulating agents
with a multitude of off-target effects. This is particularly rele-
vant in the current era when a number of new and exciting
agents are being developed for the treatment of CLL.
The results of this study also underscore the importance
of large randomized multi-institutional trials as essential for
making practice-changing therapeutic decisions because non-
randomized phase 2 data may be subject to bias and poten-
tially inaccurate results. This has been more relevant in the
case of CLL as, historically, a number of therapeutic regi-
mens that are commonly utilized in the community were
based on small, non-randomized phase 2 studies (Keating
et al, 2005; Tam et al, 2008; Fischer et al, 2012).
Fludarabine, cyclophosphamide and rituximab is currently
considered the standard of care regimen for the first line treat-
ment of young (<65 years old) and fit patients with CLL (Hal-
lek et al, 2010). Recent results from the large CLL-10 trial
further establishes the efficacy of FCR over bendamustine and
rituximab (BR) in patients with untreated CLL, albeit with a
higher toxicity incidence (Eichhorst et al, 2013). Therapy for
relapsed disease is more challenging and complicated by
prolonged cytopenias and resultant infectious complications
(Robak et al, 2010). The LUCID trial revealed that most
patients who receive FCR had a grade 3 or worse treatment-
related AE (80% for FCR+L vs. 78% for FCR). Treatment-
related events resulted in study discontinuation in more than
30% of the patients. A significant number of patients also had
prolonged cytopenias that required interventions. In the era of
targeted therapies and the advent of kinase inhibitors, it would
be important to combine various agents to acheive maximal
benefit and deeper responses. Ideally these combinations
Table III. Adverse Events (N = 615).
FCR+L
(N = 310)
FCR
(N = 305)
Subjects with an event, n (%) 307 (99) 296 (97)
Subjects with a death event, n (%)* 15 (5) 22 (7)
Subjects with a study-related event
(possible, related, or unknown
relationship to any study drug), n (%)
301 (97) 286 (94)
Subjects with a lumiliximab-related event
(possible, related, or unknown
relationship to lumiliximab), n (%)
235 (76) 0
Subjects discontinuing treatment
due to an event, n (%)
95 (31) 88 (29)
Subjects withdrawing from study
due to an event, n (%)
27 (9) 32 (10)
Subjects with a serious adverse
event, n (%)
125 (40) 119 (39)
Subjects with a study-related event (grade 3 or above), n (%)
Grade 3 115 (37) 104 (34)
Grade 4 124 (40) 121 (40)
Grade 5 9 (3) 11 (4)
Subjects with a serious adverse event (grade 3 or above)
Grade 3 49 (16) 54 (18)
Grade 4 34 (11) 25 (8)
Grade 5 15 (5) 22 (7)
Leucopenia and Neutropenia, n (%) 249 (80) 245 (80)
Grade 1 6 (2) 5 (2)
Grade 2 22 (7) 25 (8)
Grade 3 107 (35) 98 (32)
Grade 4 113 (36) 116 (38)
Grade 5 1 (1) 1 (1)
Median duration of leucopenia and
neutropenia (days), n (%)
14 14
Subjects with prolonged leucopenia
(>28 d, any grade), n (%)
124 (40) 112 (37)
Incidence of thrombocytopenia, n (%) 111 (36) 96 (31)
Grade 1 18 (6) 28 (9)
Grade 2 39 (13) 21 (7)
Grade 3 42 (14) 38 (12)
Grade 4 12 (4) 9 (3)
Grade 5 0 0
Median duration of thrombocytopenia
(days)
15 15
Subjects with prolonged thrombocytopenia
(>28 d, any grade), n (%)
58 (19) 33 (11)
Incidence of anaemia, n (%) 94 (30) 107 (35)
Grade 1 19 (6) 20 (7)
Grade 2 33 (11) 42 (14)
Grade 3 26 (8) 35 (11)
Grade 4 16 (5) 9 (3)
Grade 5 0 1 (1)
Median duration of anaemia in days 11 13
Subjects with prolonged anaemia
(>28 d, any grade), n (%)
44 (14) 48 (16)
Autoimmune cytopenias, n (%)
Autoimmune haemolytic anaemia (AIHA) 5 (1) 8 (3)
Immune thrombocytopenia (ITP) 0 2 (<1)
Table III. (Continued)
FCR+L
(N = 310)
FCR
(N = 305)
Autoimmune neutropenia 0 1 (<1)
New diagnoses of secondary cancers, n (%) 17 (5) 28 (9)
MDS/AML, n (%) 2 (<1) 4 (1)
FCR, fludarabine, cyclophosphamide and rituximab: FCR+L, FCR
and lumiliximab; MDS, myelodysplastic syndrome; AML, acute mye-
loid leukaemia.
*One patient in both arms had Richter transformation and one
patient had disease progression in the FCR arm.
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would not be based on chemotherapy backbones, given that
long term data from fludarabine-based combination regimen
use suggests a high incidence of secondary cancers (Tam et al,
2006; Zhou et al, 2012; Strati et al, 2013), a fact that was not
addressed by this study given the early termination. Neverthe-
less, this largest study of FCR in patients with relapsed CLL
highlights the significant toxicity with the use of FCR in the
relapsed setting, and underscores the importance of the need
to find better tolerated and more efficacious therapeutic regi-
mens for patients with relapsed CLL.
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